Science and technology to help take off, innovation to promote development

-- "Shuganning injection clinical and experimental research" project start-up documentary

Shuganning Injection Clinical and Experimental Research Project Launch Meeting

Mr. Xiong Yigang, Chairman of Ruihe Pharmaceutical, exchanged the text of the subject agreement with Professor Duan Zhongping.

Autumn in October, spring and autumn.

Initiated by Guizhou Ruihe Pharmaceutical Co., Ltd., and led by Professor Duan Zhongping, chairman of the Hepatology Branch of the Chinese Medical Association and director of the Institute of Hepatology and Translational Medicine of Capital Medical University, beijing You'an Hospital Affiliated to Capital Medical University, the Fifth Medical Center of the PLA General Hospital, the Third Hospital of Hebei Medical University, the Second Affiliated Hospital of Xi'an Jiaotong University, the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, and the Affiliated Hospital of Guizhou Medical University The launching ceremony of the scientific research project "Shuganning Injection Clinical and Experimental Research" jointly implemented by 6 well-known domestic medical institutions in the field of liver diseases was held in Beijing on November 21, 2018.

For a long time, the role and value of traditional Chinese medicine in the diagnosis and treatment of liver disease have received more and more attention from clinical doctors and patients and the whole society. Actively explore the high-level evidence-based evidence of traditional Chinese medicine in the diagnosis and treatment of liver disease, and in-depth study of the role of core components and their key mechanisms. It is the guiding ideology and research direction of the scientific research project of "Shuganning Injection Clinical and Experimental Research.

Under the background of the new era of continuous advancement of reforms in the field of medicine and health, as a high-tech pharmaceutical company in western my country, Ruihe Pharmaceuticals has the courage to challenge itself, take the initiative, and invest heavily in in-depth research on clinical and experimental Chinese medicine injections. A new model of integrated research on traditional Chinese medicine industry-university-research contributes corporate wisdom and strength to the revitalization of Chinese medicine.

Speech by Professor Duan Zhongping, Chairman of Hepatology Branch of Chinese Medical Association

As the leader of this scientific research project, Professor Duan Zhongping, chairman of the Hepatology Branch of the Chinese Medical Association, Beijing You'an Hospital Affiliated to Capital Medical University, and Director of the Institute of Hepatology and Translational Medicine of Capital Medical University, first introduced the project approval process and research significance. And expressed admiration for the enterprising behavior of the enterprise to challenge itself and be brave in innovation. He said that Shuganning has been used in our hospital for many years, with good curative effect and high safety. This high-level evidence study will certainly promote the further release of the clinical application value of the drug, bring new evidence-based evidence for the treatment of liver disease, and promote the research of traditional Chinese medicine to a new level.

Speech by Vice President Sun liguang of Capital Medical University

Vice President Sun liguang of Capital Medical University spared no effort to come to the meeting site, which brought great encouragement to this scientific research activity. In his speech, he said that Capital Medical University will fully support the research and promote the sustainable and healthy development of the national pharmaceutical industry.

Speech by Mr. Xiong Yigang, Chairman of Guizhou Ruihe Pharmaceutical Co., Ltd.

Mr. Xiong Yigang, chairman of Guizhou Ruihe Pharmaceutical Co., Ltd., on behalf of the enterprise, expressed heartfelt thanks and respect to Professor Duan Zhongping of Beijing You'an Hospital of Capital Medical University and experts and scholars from five other well-known hospitals for attending the kick-off meeting and actively participating in this scientific research project. After summarizing that the subject product Shuganning has been in clinical use for 20 years and its efficacy and safety have been widely praised in clinical practice, it is emphasized that carrying out high-level evidence-based research on "traditional Chinese medicine injection" and promoting the innovative development of basic research in traditional Chinese medicine is worthy of enterprise investment and in-depth research and continuous development. It said that Ruihe Pharmaceutical will fully cooperate with the research unit to carry out the subject research and wish the smooth implementation and successful completion of this research.

All the staff who participated in the project kick-off meeting took a group photo as a souvenir.

Professor An Wei from Beijing You'an Hospital of Capital Medical University, Professor Xin Shaojie from the Fifth Medical Center of the PLA General Hospital, Professor Nan Yuemin from the Third Hospital of Hebei Medical University, Professor Dang Shuangsuo from the Second Affiliated Hospital of Xi'an Jiaotong University, and Affiliated to Tongji Medical College of Huazhong University of Science and Technology Professor Zheng Xin from Union Hospital, professor Cheng Mingliang of the Affiliated Hospital of Guizhou Medical University and other well-known scholars and experts put forward many beneficial ideas and improvement suggestions on the implementation plan of the sub-topic "Clinical Research on the Effectiveness and Safety of Shuganning Injection in the Treatment of Chronic Hepatitis B Liver Injury" under the "Clinical and Experimental Research of Shuganning Injection", which enriched and improved the content of clinical research and made the research plan more operable and flexible.

This study will last for two years, and it is expected that this study will bring new thinking and breakthroughs to the clinical application and development direction of traditional Chinese medicine injections.

The kick-off meeting of this scientific research project has received attention and reports from many media such as Health News, Science and Technology Daily, Health Times, International Liver Disease Network, and Beijing Liver and Courage Foundation.

Zhao Yun, general manager of Guizhou Ruihe Pharmaceutical Co., Ltd., and heads of marketing, sales, academic, and regional departments attended the kick-off meeting.